This decision is based on the randomised MITIGATE trial data, which showed the antibody’s potential to reduce disease activity by minimising flares in individuals, upholding its established safety
This clearance comes after the company’s receipt of approval from New Zealand’s Medsafe last month for clinical trial application to commence a first-in-human study of the therapy. During
This status is aimed at facilitating the development and speeding up the review process for drugs that address serious conditions and fill unmet medical needs. Biogen development head
This announcement follows the US Food and Drug Administration’s (FDA) orphan drug designation granted to deucrictibant for the same indication in March 2022. According to the company, this
This new option is intended for patients whose COPD is not sufficiently controlled with existing treatment. COPD is a chronic respiratory disease that progressively impairs lung function and
Acoramidis is a selective small molecule that is orally administered. ATTR-CM is a progressive, restrictive cardiomyopathy that leads to heart failure. BridgeBio Cardiorenal chief medical officer Dr Jonathan
The treatment, designed to be administered either as an injectable or an oral medication, utilises the regulation of the brain’s nitric oxide (NO) levels to influence neurological function.
The centre will focus on the early detection of diseases and design treatments for improved patient outcomes using precision medicine. Metabolomics, the study of small molecules or metabolites,
The therapy claims to be the only oral inhibitor targeting the alternative complement pathway, specifically addressing what is believed to be the root cause of the disease. Usually
This collaboration leverages Porton Advanced’s cell and gene therapy manufacturing offerings and Artemis cell receptor as well as the E‑ALPHA antibody discovery platforms of Eureka. Through this partnership, Porton Advanced
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.